Pomalyst Alternatives Compared
| Pomalyst (pomalidomide) | Abecma (idecabtagene vicleucel) | Tecvayli (teclistamab) |
|
|---|
| Pomalyst (pomalidomide) | Abecma (idecabtagene vicleucel) | Tecvayli (teclistamab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Multiple Myeloma, Kaposi's Sarcoma. Pomalyst may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Myeloma. Abecma may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Myeloma. Tecvayli may also be used for purposes not listed in this medication guide. |
Related suggestions Multiple Myeloma
|
|||||||||||||||||||||||
| More about Pomalyst (pomalidomide) | More about Abecma (idecabtagene vicleucel) | More about Tecvayli (teclistamab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Pomalyst has an average rating of 10.0 out of 10 from a total of 3 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
Tecvayli has an average rating of 9.7 out of 10 from a total of 3 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Pomalyst prices |
View all Abecma prices |
View all Tecvayli prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
9.5 hours |
N/A |
N/A |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 381 drugs are known to interact with Pomalyst:
|
A total of 204 drugs are known to interact with Abecma:
|
A total of 409 drugs are known to interact with Tecvayli:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
February 08, 2013 |
N/A |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.